Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04746911
Status:
COMPLETED
Last Update Posted:
2023-03-10
First Post:
2021-02-05
Brief Title:
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis ARQ-151-216
Sponsor:
Arcutis Biotherapeutics Inc
Organization:
Arcutis Biotherapeutics Inc
Study Overview
Official Title:
An Open Label 4-Week Phase 2 Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 03 Administered QD in Pediatric Subjects Ages 2 to 5 Years Old With Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 open label maximal usage PK and safety study of ARQ-151 cream 03 in pediatric subjects ages 2 to 5 years old with plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None